Bellerophon Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2013 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Bellerophon Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2013 to 2022.
  • Bellerophon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2023 was $21K, a 90.3% decline year-over-year.
  • Bellerophon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2023 was $580K, a 19.9% decline year-over-year.
  • Bellerophon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $786K, a 30.2% decline from 2021.
  • Bellerophon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $1.13M, a 31% decline from 2020.
  • Bellerophon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $1.63M, a 24.1% decline from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $786K -$340K -30.2% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-31
2021 $1.13M -$507K -31% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 $1.63M -$519K -24.1% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-31
2019 $2.15M -$803K -27.2% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-31
2018 $2.96M +$114K +4.01% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-11
2017 $2.84M +$83K +3.01% Jan 1, 2017 Dec 31, 2017 10-K 2020-04-06
2016 $2.76M +$1.01M +57.5% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-14
2015 $1.75M -$88K -4.79% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-15
2014 $1.84M +$118K +6.86% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-13
2013 $1.72M Jan 1, 2013 Dec 31, 2013 10-K 2016-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.